1
|
Feliz Morel ÁJ, Hasanovic A, Morin A, Prunier C, Magnone V, Lebrigand K, Aouad A, Cogoluegnes S, Favier J, Pasquier C, Mus-Veteau I. Persistent Properties of a Subpopulation of Cancer Cells Overexpressing the Hedgehog Receptor Patched. Pharmaceutics 2022; 14:pharmaceutics14050988. [PMID: 35631574 PMCID: PMC9146430 DOI: 10.3390/pharmaceutics14050988] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 04/22/2022] [Accepted: 04/29/2022] [Indexed: 02/01/2023] Open
Abstract
Despite the development of new therapeutic strategies, cancer remains one of the leading causes of mortality worldwide. One of the current major challenges is the resistance of cancers to chemotherapy treatments inducing metastases and relapse of the tumor. The Hedgehog receptor Patched (Ptch1) is overexpressed in many types of cancers. We showed that Ptch1 contributes to the efflux of doxorubicin and plays an important role in the resistance to chemotherapy in adrenocortical carcinoma (ACC), a rare cancer which presents strong resistance to the standard of care chemotherapy treatment. In the present study, we isolated and characterized a subpopulation of the ACC cell line H295R in which Ptch1 is overexpressed and more present at the cell surface. This cell subpopulation is more resistant to doxorubicin, grows as spheroids, and has a greater capability of clonogenicity, migration, and invasion than the parental cells. Xenograft experiments performed in mice and in ovo showed that this cell subpopulation is more tumorigenic and metastatic than the parental cells. These results suggest that this cell subpopulation has cancer stem-like or persistent cell properties which were strengthened by RNA-seq. If present in tumors from ACC patients, these cells could be responsible for therapy resistance, relapse, and metastases.
Collapse
Affiliation(s)
- Álvaro Javier Feliz Morel
- Université Côte d’Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), 06560 Valbonne, France; (Á.J.F.M.); (A.H.); (V.M.); (K.L.); (A.A.); (S.C.)
| | - Anida Hasanovic
- Université Côte d’Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), 06560 Valbonne, France; (Á.J.F.M.); (A.H.); (V.M.); (K.L.); (A.A.); (S.C.)
| | - Aurélie Morin
- Université de Paris, PARCC, INSERM, Equipe Labellisée par la Ligue Contre le Cancer, CEDEX 15, 75737 Paris, France; (A.M.); (J.F.)
| | - Chloé Prunier
- INOVOTION, Biopolis-5 Av. du Grand Sablon, 38700 La Tronche, France;
| | - Virginie Magnone
- Université Côte d’Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), 06560 Valbonne, France; (Á.J.F.M.); (A.H.); (V.M.); (K.L.); (A.A.); (S.C.)
| | - Kevin Lebrigand
- Université Côte d’Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), 06560 Valbonne, France; (Á.J.F.M.); (A.H.); (V.M.); (K.L.); (A.A.); (S.C.)
| | - Amaury Aouad
- Université Côte d’Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), 06560 Valbonne, France; (Á.J.F.M.); (A.H.); (V.M.); (K.L.); (A.A.); (S.C.)
| | - Sarah Cogoluegnes
- Université Côte d’Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), 06560 Valbonne, France; (Á.J.F.M.); (A.H.); (V.M.); (K.L.); (A.A.); (S.C.)
| | - Judith Favier
- Université de Paris, PARCC, INSERM, Equipe Labellisée par la Ligue Contre le Cancer, CEDEX 15, 75737 Paris, France; (A.M.); (J.F.)
| | - Claude Pasquier
- Université Côte d’Azur, CNRS-UMR7271, Laboratoire d’Informatique, Signaux et Systèmes de Sophia Antipolis (I3S), 06560 Valbonne, France;
| | - Isabelle Mus-Veteau
- Université Côte d’Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), 06560 Valbonne, France; (Á.J.F.M.); (A.H.); (V.M.); (K.L.); (A.A.); (S.C.)
- Correspondence:
| |
Collapse
|
2
|
Methiothepin Increases Chemotherapy Efficacy against Resistant Melanoma Cells. Molecules 2021; 26:molecules26071867. [PMID: 33810240 PMCID: PMC8037503 DOI: 10.3390/molecules26071867] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Revised: 03/16/2021] [Accepted: 03/23/2021] [Indexed: 11/16/2022] Open
Abstract
We previously reported that methiothepin, a small molecule known as a nonselective serotonin 5-HT receptor antagonist, inhibited the doxorubicin efflux activity of the Hedgehog receptor Ptch1 and enhanced the cytotoxic, pro-apoptotic, anti-proliferative, and anti-clonogenic effects of doxorubicin on adrenocortical carcinoma cells. Here, we show that methiothepin also inhibits doxorubicin efflux and increases doxorubicin cytotoxicity in melanoma cells which endogenously overexpress Ptch1. Melanoma patients having the BRAFV600E mutation are treated with vemurafenib, an inhibitor of BRAFV600E, often in combination with trametinib, an inhibitor of MEK. Almost all patients ultimately acquire resistance to the treatment leading to disease progression. Here, we report that methiothepin overcomes the resistance of BRAFV600E melanoma cells by enhancing the cytotoxicity of vemurafenib and trametinib on these cells leading to melanoma cells death. We observe that the addition of methiothepin to vemurafenib prevents migration of resistant melanoma cells more efficiently than vemurafenib alone. Our results provide an additional proof that Ptch1 drug efflux inhibition increases the effectiveness of anti-cancer treatments and overcomes resistance of melanoma cells expressing Ptch1.
Collapse
|
3
|
Hasanovic A, Simsir M, Choveau FS, Lalli E, Mus-Veteau I. Astemizole Sensitizes Adrenocortical Carcinoma Cells to Doxorubicin by Inhibiting Patched Drug Efflux Activity. Biomedicines 2020; 8:biomedicines8080251. [PMID: 32751066 PMCID: PMC7460240 DOI: 10.3390/biomedicines8080251] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Revised: 07/22/2020] [Accepted: 07/24/2020] [Indexed: 01/01/2023] Open
Abstract
Adrenocortical carcinoma (ACC) presents a high risk of relapse and metastases with outcomes not improving despite extensive research and new targeted therapies. We recently showed that the Hedgehog receptor Patched is expressed in ACC, where it strongly contributes to doxorubicin efflux and treatment resistance. Here, we report the identification of a new inhibitor of Patched drug efflux, the anti-histaminergic drug astemizole. We show that astemizole enhances the cytotoxic, proapoptotic, antiproliferative and anticlonogenic effects of doxorubicin on ACC cells at concentrations of astemizole or doxorubicin that are not effective by themselves. Our results suggest that a low concentration of astemizole sensitizes ACC cells to doxorubicin, which is a component of the standard treatment for ACC composed of etoposide, doxorubicin, cisplatin and mitotane (EDPM). Patched uses the proton motive force to efflux drugs. This makes its function specific to cancer cells, thereby avoiding toxicity issues that are commonly observed with inhibitors of ABC multidrug transporters. Our data provide strong evidence that the use of astemizole or a derivative in combination with EDPM could be a promising therapeutic option for ACC by increasing the treatment effectiveness at lower doses of EDPM, which would reduce the severe side effects of this regimen.
Collapse
|
4
|
Signetti L, Elizarov N, Simsir M, Paquet A, Douguet D, Labbal F, Debayle D, Di Giorgio A, Biou V, Girard C, Duca M, Bretillon L, Bertolotto C, Verrier B, Azoulay S, Mus-Veteau I. Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf V600E Melanoma. Cancers (Basel) 2020; 12:cancers12061500. [PMID: 32526884 PMCID: PMC7352342 DOI: 10.3390/cancers12061500] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 06/03/2020] [Accepted: 06/05/2020] [Indexed: 12/25/2022] Open
Abstract
Melanoma patients harboring the BRAFV600E mutation are treated with vemurafenib. Almost all of them ultimately acquire resistance, leading to disease progression. Here, we find that a small molecule from a marine sponge, panicein A hydroquinone (PAH), overcomes resistance of BRAFV600E melanoma cells to vemurafenib, leading to tumor elimination in corresponding human xenograft models in mice. We report the synthesis of PAH and demonstrate that this compound inhibits the drug efflux activity of the Hedgehog receptor, Patched. Our SAR study allowed identifying a key pharmacophore responsible for this activity. We showed that Patched is strongly expressed in metastatic samples from a cohort of melanoma patients and is correlated with decreased overall survival. Patched is a multidrug transporter that uses the proton motive force to efflux drugs. This makes its function specific to cancer cells, thereby avoiding toxicity issues that are commonly observed with inhibitors of ABC multidrug transporters. Our data provide strong evidence that PAH is a highly promising lead for the treatment of vemurafenib resistant BRAFV600E melanoma.
Collapse
Affiliation(s)
- Laurie Signetti
- Université Côte d’Azur, CNRS, IPMC, 660 Route des Lucioles, 06560 Valobonne, France; (L.S.); (M.S.); (A.P.); (D.D.); (F.L.); (D.D.)
| | - Nelli Elizarov
- Université Côte d’Azur, CNRS, ICN, 28 Avenue Valrose, 06108 Nice, CEDEX 2, France; (N.E.); (A.D.G.); (M.D.)
| | - Méliné Simsir
- Université Côte d’Azur, CNRS, IPMC, 660 Route des Lucioles, 06560 Valobonne, France; (L.S.); (M.S.); (A.P.); (D.D.); (F.L.); (D.D.)
| | - Agnès Paquet
- Université Côte d’Azur, CNRS, IPMC, 660 Route des Lucioles, 06560 Valobonne, France; (L.S.); (M.S.); (A.P.); (D.D.); (F.L.); (D.D.)
| | - Dominique Douguet
- Université Côte d’Azur, CNRS, IPMC, 660 Route des Lucioles, 06560 Valobonne, France; (L.S.); (M.S.); (A.P.); (D.D.); (F.L.); (D.D.)
| | - Fabien Labbal
- Université Côte d’Azur, CNRS, IPMC, 660 Route des Lucioles, 06560 Valobonne, France; (L.S.); (M.S.); (A.P.); (D.D.); (F.L.); (D.D.)
| | - Delphine Debayle
- Université Côte d’Azur, CNRS, IPMC, 660 Route des Lucioles, 06560 Valobonne, France; (L.S.); (M.S.); (A.P.); (D.D.); (F.L.); (D.D.)
| | - Audrey Di Giorgio
- Université Côte d’Azur, CNRS, ICN, 28 Avenue Valrose, 06108 Nice, CEDEX 2, France; (N.E.); (A.D.G.); (M.D.)
| | - Valérie Biou
- CNRS, IBPC, Sorbonne Paris Cité, Laboratoire de Biologie Physico-Chimique des Protéines Membranaires, Institut de Biologie Physico-Chimique, University Paris Diderot, 13 rue Pierre et Marie Curie, 75005 Paris, France;
| | - Christophe Girard
- Université Côte d’Azur, INSERM, CNRS, C3M, Bâtiment Universitaire ARCHIMED 151 Route Saint Antoine de Ginestière BP 2 3194, 06204 Nice, CEDEX 3, France; (C.G.); (C.B.)
| | - Maria Duca
- Université Côte d’Azur, CNRS, ICN, 28 Avenue Valrose, 06108 Nice, CEDEX 2, France; (N.E.); (A.D.G.); (M.D.)
| | - Lionel Bretillon
- Centre des Sciences du Goût et de l’Alimentation, Université Bourgogne Franche-Comté CNRS, INRA, SSGA, AgroSup Dijon, F-21000 Dijon, France;
| | - Corine Bertolotto
- Université Côte d’Azur, INSERM, CNRS, C3M, Bâtiment Universitaire ARCHIMED 151 Route Saint Antoine de Ginestière BP 2 3194, 06204 Nice, CEDEX 3, France; (C.G.); (C.B.)
| | - Bernard Verrier
- Adjuvatis SAS, IBCP, 7 Passage du Vercors—69007 Lyon, France;
| | - Stéphane Azoulay
- Université Côte d’Azur, CNRS, ICN, 28 Avenue Valrose, 06108 Nice, CEDEX 2, France; (N.E.); (A.D.G.); (M.D.)
- Correspondence: (S.A.); (I.M.-V.)
| | - Isabelle Mus-Veteau
- Université Côte d’Azur, CNRS, IPMC, 660 Route des Lucioles, 06560 Valobonne, France; (L.S.); (M.S.); (A.P.); (D.D.); (F.L.); (D.D.)
- Correspondence: (S.A.); (I.M.-V.)
| |
Collapse
|
5
|
Hasanovic A, Mus-Veteau I. Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency. Cells 2018; 7:cells7080107. [PMID: 30110910 PMCID: PMC6115939 DOI: 10.3390/cells7080107] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2018] [Revised: 08/08/2018] [Accepted: 08/11/2018] [Indexed: 12/22/2022] Open
Abstract
One of the crucial challenges in the clinical management of cancer is resistance to chemotherapeutics. Multidrug resistance (MDR) has been intensively studied, and one of the most prominent mechanisms underlying MDR is overexpression of adenosine triphosphate (ATP)-binding cassette (ABC) transporters. Despite research efforts to develop compounds that inhibit the efflux activity of ABC transporters and thereby increase classical chemotherapy efficacy, to date, the Food and Drug Administration (FDA) has not approved the use of any ABC transporter inhibitors due to toxicity issues. Hedgehog signaling is aberrantly activated in many cancers, and has been shown to be involved in chemotherapy resistance. Recent studies showed that the Hedgehog receptor Ptch1, which is over-expressed in many recurrent and metastatic cancers, is a multidrug transporter and it contributes to the efflux of chemotherapeutic agents such as doxorubicin, and to chemotherapy resistance. Remarkably, Ptch1 uses the proton motive force to efflux drugs, in contrast to ABC transporters, which use ATP hydrolysis. Indeed, the “reversed pH gradient” that characterizes cancer cells, allows Ptch1 to function as an efflux pump specifically in cancer cells. This makes Ptch1 a particularly attractive therapeutic target for cancers expressing Ptch1, such as lung, breast, prostate, ovary, colon, brain, adrenocortical carcinoma, and melanoma. Screening of chemical libraries have identified several molecules that are able to enhance the cytotoxic effect of different chemotherapeutic agents by inhibiting Ptch1 drug efflux activity in different cancer cell lines that endogenously over-express Ptch1. In vivo proof of concept has been performed in mice where combining one of these compounds with doxorubicin prevented the development of xenografted adrenocortical carcinoma tumors more efficiently than doxorubicin alone, and without obvious undesirable side effects. Therefore, the use of a Ptch1 drug efflux inhibitor in combination with classical or targeted therapy could be a promising therapeutic option for Ptch1-expressing cancers.
Collapse
Affiliation(s)
- Anida Hasanovic
- Université Côte d'Azur, Campus Valrose, 06100 Nice, France.
- CNRS UMR7275, Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, 06560 Valbonne, France.
- NEOGENEX CNRS International Associated Laboratory, Sophia Antipolis, 06560 Valbonne, France.
| | - Isabelle Mus-Veteau
- Université Côte d'Azur, Campus Valrose, 06100 Nice, France.
- CNRS UMR7275, Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, 06560 Valbonne, France.
- NEOGENEX CNRS International Associated Laboratory, Sophia Antipolis, 06560 Valbonne, France.
| |
Collapse
|
6
|
Hasanovic A, Ruggiero C, Jung S, Rapa I, Signetti L, Ben Hadj M, Terzolo M, Beuschlein F, Volante M, Hantel C, Lalli E, Mus-Veteau I. Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo. Int J Cancer 2018; 143:199-211. [PMID: 29411361 DOI: 10.1002/ijc.31296] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2017] [Revised: 12/22/2017] [Accepted: 01/23/2018] [Indexed: 02/06/2023]
Abstract
One of the crucial challenges in the clinical management of cancer is the resistance to chemotherapeutics. We recently demonstrated that the Hedgehog receptor Patched, which is overexpressed in many recurrent and metastatic cancers, is a multidrug transporter for chemotherapeutic agents such as doxorubicin. The present work provides evidences that Patched is expressed in adrenocortical carcinoma (ACC) patients, and is a major player of the doxorubicin efflux and the doxorubicin resistance in the human ACC cell line H295R. We discovered that methiothepin inhibits the doxorubicin efflux activity of Patched. This drug-like molecule enhances the cytotoxic, pro-apoptotic, antiproliferative and anticlonogenic effects of doxorubicin on ACC cells which endogenously overexpress Patched, and thereby mitigates the resistance of these cancer cells to doxorubicin. Moreover, we report that in mice the combination of methiothepin with doxorubicin prevents the development of xenografted ACC tumors more efficiently than doxorubicin alone by enhancing the accumulation of doxorubicin specifically in tumors without obvious undesirable side effects. Our results suggest that the use of an inhibitor of Patched drug efflux such as methiothepin in combination with doxorubicin could be a promising therapeutic option for adrenocortical carcinoma, and most likely also for other Patched-expressing cancers.
Collapse
Affiliation(s)
- Anida Hasanovic
- Université Côte d'Azur, Sophia Antipolis, Valbonne, France.,CNRS UMR7275, Sophia Antipolis, Valbonne, France.,NEOGENEX CNRS International Associated Laboratory, Sophia Antipolis, Valbonne, France.,Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France
| | - Carmen Ruggiero
- Université Côte d'Azur, Sophia Antipolis, Valbonne, France.,CNRS UMR7275, Sophia Antipolis, Valbonne, France.,NEOGENEX CNRS International Associated Laboratory, Sophia Antipolis, Valbonne, France.,Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France
| | - Sara Jung
- Endocrine Research Unit, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität, Munich, Germany
| | - Ida Rapa
- Department of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy
| | - Laurie Signetti
- Université Côte d'Azur, Sophia Antipolis, Valbonne, France.,CNRS UMR7275, Sophia Antipolis, Valbonne, France.,NEOGENEX CNRS International Associated Laboratory, Sophia Antipolis, Valbonne, France.,Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France
| | - Monia Ben Hadj
- Université Côte d'Azur, Sophia Antipolis, Valbonne, France.,CNRS UMR7275, Sophia Antipolis, Valbonne, France.,NEOGENEX CNRS International Associated Laboratory, Sophia Antipolis, Valbonne, France.,Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France
| | - Massimo Terzolo
- Department of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy
| | - Felix Beuschlein
- Endocrine Research Unit, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität, Munich, Germany.,Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zurich, Switzerland
| | - Marco Volante
- Department of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy
| | - Constanze Hantel
- Endocrine Research Unit, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität, Munich, Germany.,Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zurich, Switzerland
| | - Enzo Lalli
- Université Côte d'Azur, Sophia Antipolis, Valbonne, France.,CNRS UMR7275, Sophia Antipolis, Valbonne, France.,NEOGENEX CNRS International Associated Laboratory, Sophia Antipolis, Valbonne, France.,Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France
| | - Isabelle Mus-Veteau
- Université Côte d'Azur, Sophia Antipolis, Valbonne, France.,CNRS UMR7275, Sophia Antipolis, Valbonne, France.,NEOGENEX CNRS International Associated Laboratory, Sophia Antipolis, Valbonne, France.,Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France
| |
Collapse
|